Pharmaceutical immunoglobulin G impairs anti-carcinoma activity of oxaliplatin in colon cancer cells.

ABSTRACT:

Background

Recent evidence proves that intravenous human immunoglobulin G (IgG) can impair cancer cell viability. However, no study evaluated whether IgG application benefits cancer patients receiving chemotherapeutics.

Methods

Influence of pharmaceutical-grade human IgG on the viability of a series of patient-derived colon cancer cell lines with and without chemotherapeutic intervention was determined. Cell death was analysed flow cytometrically. In addition, the influence of oxaliplatin and IgG on the ERK1/2-signalling pathway was evaluated by western blots.

Results

We evaluated the effects of pharmaceutical IgG, such as PRIVIGEN^® IgG and Tonglu^® IgG, in combination with chemotherapeutics. We did not observe any significant effects of IgG on tu

SUBMITTER: Shang Y 

PROVIDER: S-EPMC8039037 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature